Anticholinergic Medication Use and Risk of Pneumonia in Elderly Adults: A Nested Case-Control Study

2016 ◽  
Vol 64 (2) ◽  
pp. 394-400 ◽  
Author(s):  
Satabdi Chatterjee ◽  
Ryan M. Carnahan ◽  
Hua Chen ◽  
Holly M. Holmes ◽  
Michael L. Johnson ◽  
...  
2021 ◽  
Vol 50 (Supplement_1) ◽  
Author(s):  
Hoda Abdel Magid ◽  
Barbara Topal ◽  
Valerie McGuire ◽  
Jessica Hinman ◽  
Edward Karasakis ◽  
...  

Abstract Background We investigated the association between hypertension, ischemic heart disease, heart failure, acute myocardial infarction, and atrial fibrillation with the risk of amyotrophic lateral sclerosis (ALS). This study also examined associations with use of angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptors blockers (ARBs), calcium channel blockers, beta blockers, and antiarrhythmics Methods We conducted a population-based nested case-control study in the Medicare fee for service population, including 3,714 enrollees ages 65 and above with newly diagnosed ALS between 2006-2014. Cases were compared with 18,750 sex-, age, county, and enrollment-matched controls. Odds ratios (OR) and 95% Confidence Intervals (CIs) were estimated using conditional logistic regression models adjusting for diabetes, obesity, tobacco use, socioeconomic status, and controlling for confounding by indication. Medication use was identified through claims pharmacy data and similarly analyzed using a dose response approach. Results The fully adjusted OR for any CVD diagnosis was 0.93 (95% CI 0.86–1.02). Our results varied across cause-specific CVD diagnoses. We observed inverse associations for heart failure (OR 0.79; 95% CI 0.70–0.89) and atrial fibrillation (OR 0.81; 95% CI 0.76–0.92). ALS risk was reduced with use of ACEIs (OR 0.84; 95% CI 0.77–0.91), calcium channel blockers (OR 0.64; 95% CI 0.59–0.70), and beta blockers (OR 0.76; 95% CI 0.71–0.83). Conclusions In this large population-based Medicare study, the risk of ALS was 7% lower among individuals with any CVD diagnosis. Key messages Our findings suggest having a cardiovascular condition or use of a CVD medication may be protective for ALS.


2019 ◽  
Vol 181 (5) ◽  
pp. 499-507 ◽  
Author(s):  
Ida Kim Wium-Andersen ◽  
Merete Osler ◽  
Martin Balslev Jørgensen ◽  
Jørgen Rungby ◽  
Marie Kim Wium-Andersen

Objective Diabetes is a risk factor for dementia, but whether antidiabetic medication decreases the risk is unclear. We examined the association between antidiabetic medication and dementia. Design We performed a nested case–control study within a cohort of all 176 250 patients registered with type 2 diabetes in the Danish National Diabetes Register between 1995 and 2012. This population was followed for dementia diagnosis or anti-dementia medication use until May 2018. Using risk-set sampling, each dementia case (n = 11 619) was matched on follow-up time and calender year of dementia with four controls randomly selected among cohort members without dementia (n = 46 476). Ever use and mean daily defined dose of antidiabetic medication was categorized in types (insulin, metformin, sulfonylurea and glinides combined, glitazone, dipeptidyl peptidase 4 (DPP4) inhibitors, glucagon-like peptide 1 (GLP1) analogs, sodium-glucose transport protein 2 (SGLT2) inhibitors and acarbose). Methods Conditional logistic regression models were fitted to calculate odds ratios (ORs) for dementia associated with antidiabetic medication use, adjusting for potential confounders. Results Use of metformin, DPP4 inhibitors, GLP1 analogs, and SGLT2 inhibitors were associated with lower odds of dementia after multible adjustments (ORs of 0.94 (95% confidence interval (CI): 0.89–0.99), 0.80 (95% CI 0.74–0.88), 0.58 (95% CI: 0.50–0.67), and 0.58 (95% CI: 0.42–0.81), respectively), with a gradual decrease in odds of dementia for each increase in daily defined dose. Analyses of the most frequent treatment regimes did not show any synergistic effects of combined treatment. Conclusion Use of metformin, DPP4 inhibitors, GLP1 analogs and SGLT2 inhibitors was associated with lower risk of dementia in patients with diabetes.


Sign in / Sign up

Export Citation Format

Share Document